Citius Pharmaceuticals Announces FDA Acceptance of IND Applicati
154
CTXR: Citius Pharmaceuticals, Inc. 2022-02-15 09:15:00 Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids